

1. Record Nr.	UNISA990000788760203316
Autore	MAZZARINO, Santo
Titolo	L' impero romano / Santo Mazzarino
Pubbl/distr/stampa	Roma : Laterza
ISBN	88-420-2377-9 88-420-2401-5
Descrizione fisica	v ; 21 cm
Collana	Biblioteca universale Laterza ; 108-109
Disciplina	937.06
Soggetti	Impero romano - Storia
Collocazione	IX.4. 42/1(VARIE COLL. 552 108) IX.4. 42/1b(VARIE COLL. 552 108 BIS) IX.4. 42/1a(VARIE COLL. 552 108 A) IX.4. 42/2(VARIE COLL. 552 109) IX.4. 42/2a(VARIE COLL. 552 109 BIS)
Lingua di pubblicazione	Italiano
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Vol.1. : 6. ed. - 1993. - VII, 430 p. ; Vol.2. : 3. ed. - 1988. - p. VIII, 434-957

2. Record Nr.	UNINA9910483536303321
Titolo	Alternative medicine interventions for COVID-19 // Muhammad Zia-UI-Haq [and three others] editors
Pubbl/distr/stampa	Cham, Switzerland : , : Springer, , [2021] ©2021
ISBN	3-030-67989-6
Descrizione fisica	1 online resource (291 pages)
Disciplina	614.592414
Soggetti	COVID-19 (Disease) - Alternative treatment COVID-19 Medicina alternativa Llibres electrònics
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Intro -- Preface -- Contents -- About the Editors -- Chapter 1: Introduction to COVID-19 -- Introduction -- Origin of COVID -- Emergence and Epidemiology -- Human-Animal Interaction as Risk Factor -- Best Suitable Animal Model -- COVID and Animal Welfare -- Molecular Differences Between Different Animal Species -- Vaccines for COVID from Animals -- Conclusion -- References -- Chapter 2: Medicinal Plants as COVID-19 Remedy -- Introduction -- Existing Plants with Potential Therapeutic Applications for Coronavirus Family (SARS-CoV) -- Plants as Specific Inhibitors of HCoV Target Proteins -- Bupleurum Species -- Artemisia annua L. -- Isatis indigotica Fortune ex Lindl. -- Alcea digitata (Boiss.) Alef. -- Lycoris radiata (L'Her.) Herb. -- Pyrrosia lingua (Thunb.) Farw. -- Houlttuynia cordata Thunb. -- Torreya nucifera L. -- Lindera aggregata (Sims) Kosterm. -- Rheum palmatum L. -- Cerasus avium (L.) Moench. -- Polygonum multiflorum Thunb. -- Citrus aurantium L. -- Rubia tinctorum L. -- Onopordum acanthium L. -- Quercus infectoria G. Olivier -- Crataegus microphylla C. Koch -- Berberis integerrima Bunge -- Alnus japonica (Thunb.) Steud. -- Paulownia tomentosa (Thunb.) Steud. -- Psoralea corylifolia L. -- Tribulus terrestris L. -- Medicinal Plants as Potential Source of Natural

Antiviral Agents Against COVID -19 -- *Allium Sativum* (Garlic) -- *Azadirachta indica* (Neem) -- *Curcuma domestica* (Turmeric, Haldi) -- *Echinacea purpurea* L. (Echinacea) -- *Foeniculum vulgare* Mill. (Fennel) -- *Glycyrrhiza glabra* (Licorice) -- *Melissa officinalis* L. (Lemon Balm) -- *Mentha piperita* L. (Peppermint) -- *Nigella sativa* L. (Black Seeds) -- *Origanum vulgare* L. (Oregano) -- *Ocimum bacilicum* L. (Basil) -- *Rosmarinus officinalis* L. (Rosemary) -- *Salvia officinalis* L. (Sage) -- *Senna alexandrina* Mill. (Senna Makki) -- *Zingiber officinale* Rosc. (Ginger) -- Limitations.

Conclusions -- References -- Chapter 3: Traditional Chinese Medicines as Possible Remedy Against SARS-CoV-2 -- Introduction -- Traditional Chinese Medical Practices -- Laws for TCM Formulation -- Antiviral Potential of Plant Metabolites -- Structure of SARS-CoV-2 -- Relevance of SARS-CoV with SARS-CoV-2 -- Entry of SARS-CoV vs. SARS-CoV-2 into Host Cell -- TCM and SARS-CoV -- TCM and SARS-CoV-2 (COVID-19) -- Most Practiced Herbs in Formulations Against COVID-19 -- Utilization Frequency of Herbs in the Formulation of (COVID-19) Decoctions -- Approved/Proposed Decoctions with Successful Clinical Trials -- Qingfei Paidu Decoction (QFPD) (Approved) -- Huashi Baidu Decoction (HBD) (Approved) -- Xiaochaihu Decoction (XCHD) -- Xuanfei Baidu Decoction (XFBD) (Approved) -- Jinhua Qinggan (JQ) (Approved) -- Huoxiang Zhengqi (HZ) Capsule -- Lianhua Qingwen (LQ) -- Xuebijing Injection (Xbl) (Approved) -- Reduning Injection (Rdl) -- Shufeng Jiedu Capsule (SFJC) -- Ma Xing Shi Gan Decoction (MXSGD) (Approved) -- Yin Qiao San (YQS) -- Yupingfeng San (YPFS) -- Therapeutic Logic of TCM as COVID-19 Inhibitor -- Mechanism of Direct Inhibition -- TCM Targeting ACE2 -- TCM Targeting Protease -- TCM Directly Targeting DNA Via Intercalation -- TCM Directly Targeting DNA via JAK-STAT Signaling Pathway -- TCM Targeting sEH -- Targeting VEGF -- Targeting DPP4 -- Targeting JUN -- Targeting EGFR -- Targeting IL1B -- Mechanism of Indirect Mechanisms -- Anti-inflammation and Immune Regulation to Avoid Cytokine Storm -- TCM Protect Organ Damage in COVID-19 Patients -- Regulation of Renin-Angiotensin-Aldosterone System (RAAS) and Potential TCM Targets -- Cytokine-Mediated Positive and Negative Immunity -- TCM Targeting MAPK (Cytokine) -- TCM Targeting Platinum Drug Resistance (Cytokine) -- TCM Targeting Tyrosine Kinase Resistance (Cytokine). TCM Targeting Interleukins (ILs) (Cytokine) -- TCM Targeting TNF (Cytokines) -- TCM Targeting Lymphocyte-Mediated Adaptive Immune System -- Regulation of Apoptosis and Potential TCM Targets -- TCM Targeting BCL Proteins -- TCM Targeting CASP -- TCM Targeting Akt or Protein Kinase B (PKB) -- Regulation of NF-B Pathway and Potential TCM Targets -- TCM Targeting TP53 -- TCM Targeting ICAM1 -- TCM Targeting RELA -- Regulation of Arachidonic Acid Metabolism and Potential TCM Targets -- TCM Targeting cPLA2 of Arachidonic Acid Metabolism -- TCM Targeting Cyclooxygenase-2 of Arachidonic Acid Metabolism -- TCM Targeting LOX of Arachidonic Acid Metabolism -- TCM Targeting Cytochrome P450 -- TCM Targeting Leukotrienes (LTs) -- TCM Targeting CALM -- TCM Targeting HIF-1 Signaling Pathways -- TCM Targeting Endocrine Resistance -- TCM Targeting FOS -- TCM Targeting PTGS2 -- Regulation of Polyamine Metabolism and Potential TCM Targets -- TCM Targeting NOS2 and AOC1 -- TCM Targeting CCL2 -- Meta-analysis -- TCM from Chinese Combat Zone to World Combat Zone -- Shortcomings of Antiviral Medicine on COVID-19 -- Conclusions -- References -- Chapter 4: Plant-Based Natural Products: Potential Anti-COVID-19 Agents -- Introduction -- Antiviral Mechanistic Aspects of Phytochemicals -- Mechanism -- Plant Selection for Antiviral Screening -- Different Classes of Phytochemicals

as Antiviral Agents -- Alkaloids -- Flavonoids -- Classification of Flavonoids -- Chalcones -- Dihydrochalcones -- Flavones -- Flavonones -- Dihydroflavonols -- Flavonol -- Isoflavonoids -- Isoflavones -- Isoflavanones -- Neoflavonoids -- Terpenoids -- Tannins -- Vitamins -- Chromones and Coumarins -- Organosulfur Compounds -- Selenium Compounds -- Miscellaneous Antiviral Phytochemicals -- Curcumin and Its Derivative -- Chlorophyllin -- Gingerols -- Chitin and Chitosan -- Anthraquinone -- Conclusion. References -- Chapter 5: Foods as First Defense Against COVID-19 -- Introduction -- Role of Nutrition and Diet in Prevention and Management of COVID-19 -- Prioritizing Nutrition Interventions During COVID-19 -- Grains -- Vegetables and Fruits -- Nuts -- Legumes -- Meat -- Milk and Milk Products -- Herbs -- Role of Vitamins in COVID-19 -- Vitamin A -- Vitamin B -- Vitamin C -- Vitamin D -- Vitamin E -- Role of Minerals in COVID-19 -- Iron -- Selenium -- Zinc -- Magnesium -- Role of Omega-3 Polyunsaturated Fatty Acids -- Nutrients for Immune System and Resilience in COVID-19 -- Nutrition in Lowering Stress and Depression in COVID-19 -- Food Choices for Diabetic Patients During COVID-19 -- Food Choices for Cardiovascular Patients During COVID-19 -- Food Choices for Cancer Patients During COVID-19 -- Food Choices for Patients with Digestive Disorders During COVID-19 -- Food Choices for Pulmonary Disease Patients During COVID-19 -- Malnutrition May Exacerbate COVID-19 -- Nutrition and Post-COVID Recovery -- Future Perspectives -- Conclusion -- References -- Chapter 6: Drugs for the Treatment of COVID-19 -- Introduction -- Dexamethasone -- Chloroquine -- Remdesivir -- Angiotensin-Converting Enzyme Inhibitors -- Spike Protein Inhibitors -- Conclusions -- References -- Chapter 7: COVID-19 Pandemic and Vaccines -- Introduction -- COVID-19 Vaccines: A Need of Time -- Coronavirus Vaccine Development: Challenges of the Past -- Vaccine Development Strategies -- Nucleic Acid Vaccines -- Protein Subunit Vaccines -- Inactivated or Live-Attenuated Virus Vaccines -- Virus Vector-Based Vaccines -- Repurposed Vaccines for COVID-19 and Off-Target Effects of Other Vaccines -- Plant-Based Vaccines -- Animal Models for SARS-CoV-2 Studies -- Cell Culture Systems for SARS-CoV-2 Studies -- Clinical and Immunological Endpoints -- Vaccine Development Landscape. Global and Equitable Distribution of Vaccines -- Vaccine Developers and Geographical Distribution -- Conclusions -- References -- Chapter 8: Updates in Vaccine Development Against COVID-19 -- Introduction -- Sinovac Biotech, China -- Conclusions -- Bibliography -- Chapter 9: COVID-19: Recent Developments in Therapeutic Approaches -- Introduction -- Morphology of SARS-CoV-2 -- Genome Organization of SARS-CoV-2 -- Replication of SARS-CoV-2 -- Transmission and Pathogenesis of SARS-CoV-2 -- Clinical Characterization of SARS-CoV-2 -- Clinical and Laboratory Diagnosis of SARS-CoV-2 -- Therapeutic Options for the Treatment of COVID-19 -- Antivirals or Immunomodulatory Drugs for COVID-19 -- Vaccine for COVID-19 -- Plasma/Serotherapy for COVID-19 -- Alternative Therapies -- Anticoagulant Therapy -- Glucocorticoids (GC) -- Stem Cell-Based Therapy -- ACE-2-Mediated Therapies -- CRISPR/Cas System -- Conclusion -- References -- Index.
